RhumbLine Advisers
RAPT

RhumbLine Advisers’s RAPT Therapeutics RAPT Stock Holding History

RhumbLine Advisers’s Portfolio RAPT Stock Details RAPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-5,203
Closed -$50.8K – 4239
2025
Q1 		$50.8K Sell
5,203
-571
-10% -$5.62K ﹤0.01% 3573
2024
Q4 		$73K Hold
5,774
– – ﹤0.01% 3563
2024
Q3 		$92.8K Sell
5,774
-40
-0.7% -$809 ﹤0.01% 3517
2024
Q2 		$142K Buy
5,814
+373
+7% +$17.2K ﹤0.01% 3396
2024
Q1 		$391K Buy
5,441
+124
+2% +$17.2K ﹤0.01% 2811
2023
Q4 		$1.06M Buy
5,317
+2
+0% +$248 ﹤0.01% 2218
2023
Q3 		$707K Sell
5,315
-134
-2% -$21.9K ﹤0.01% 2399
2023
Q2 		$815K Buy
5,449
+228
+4% +$35.5K ﹤0.01% 2410
2023
Q1 		$766K Buy
5,221
+788
+18% +$159K ﹤0.01% 2248
2022
Q4 		$702K Buy
4,433
+97
+2% +$15.5K ﹤0.01% 2305
2022
Q3 		$835K Buy
4,336
+331
+8% +$62.6K ﹤0.01% 2241
2022
Q2 		$585K Buy
4,005
+1,260
+46% +$168K ﹤0.01% 2409
2022
Q1 		$483K Buy
2,745
+425
+18% +$80.3K ﹤0.01% 2438
2021
Q4 		$682K Buy
2,320
+208
+10% +$55.6K ﹤0.01% 2378
2021
Q3 		$525K Buy
2,112
+137
+7% +$36.2K ﹤0.01% 2518
2021
Q2 		$502K Buy
1,975
+681
+53% +$127K ﹤0.01% 2561
2021
Q1 		$230K Sell
1,294
-106
-8% -$17.5K ﹤0.01% 2797
2020
Q4 		$221K Buy
1,400
+154
+12% +$33.5K ﹤0.01% 2799
2020
Q3 		$321K Sell
1,246
-240
-16% -$53.3K ﹤0.01% 2487
2020
Q2 		$345K Buy
+1,486
New +$230K ﹤0.01% 2512

Other funds holding RAPT

MVM
Medicxi Ventures Management St. Helier, Jersey $982M AUM 210.17% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
FCMV
Foresite Capital Management VI Larkspur, California $460M AUM 261.77% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
CG
Column Group San Francisco, California $101M AUM 290.34% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return

RhumbLine Advisers's RAPT Position: Q2 2025 in Review

RhumbLine Advisers sold out of RAPT Therapeutics (RAPT) in Q2 2025, closing a stake of 5,203 shares — an estimated $50.8K sold.

RhumbLine Advisers first reported a position in RAPT in Q2 2020 and held it in 20 quarters. The position peaked at $1.06M in Q4 2023. 50 funds tracked by Wall St. Rank hold RAPT as of Q2 2025.

  • RhumbLine Advisers reported no remaining RAPT Therapeutics position as of Q2 2025 after selling out during the quarter.
  • RhumbLine Advisers sold 5,203 RAPT Therapeutics shares in Q2 2025, an estimated $50.8K.
  • RhumbLine Advisers first reported a position in RAPT Therapeutics in Q2 2020 and held it in 20 quarters.
  • RhumbLine Advisers's RAPT Therapeutics position peaked at $1.06M in Q4 2023.
  • 50 funds tracked by Wall St. Rank held RAPT Therapeutics as of Q2 2025.

Based on RhumbLine Advisers's 13F filing for Q2 2025, filed 12 Aug 2025.